INAFM1: A Potential Drug Target and Biomarker (G255783)

Target Name: INAFM1

NCBI ID: G255783

INAFM1

INAFM1: A Potential Drug Target and Biomarker

Introduction

Proline-rich 24 (INAFM1) is a protein that is expressed in various tissues and cells of the human body. It is a key regulator of the cell cycle and has been involved in the development and progression of many diseases, including cancer. Therefore, INAFM1 has potential as a drug target and biomarker.

Disease-related functions of INAFM1

INAFM1 has been shown to be involved in the regulation of cell cycle progression in various cell types. It plays a role in the G1 phase, where the cell prepares for cell division, and the S phase, where the DNA is replicated. shown to promote the G1/S transition by increasing the levels of the protein p21 in the cell.

In addition to its role in cell cycle regulation, INAFM1 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. It has been shown to promote the migration of cancer cells to new tissues and is also involved in the development of metastasis.

Potential drug targets

Given INAFM1's involvement in cell cycle regulation and angiogenesis, it has potential as a drug target. One potential drug that targets INAFM1 is the drug sunitinib, which is a inhibitor of the protein inhibitor of the kinase (PIKK) pathway, which is a signaling pathway that is involved in cell cycle regulation.

Sunitinib has been shown to inhibit the activity of INAFM1 and prevent its association with the endoplasmic reticulum, which is the part of the cell that stores and retrieves proteins. This inhibition of INAFM1's activity can lead to the accumulation of INAFM1 in the cell, which can potentially lead to the formation of mitotic metaphase-competent cells, which can lead to the development of cancer.

Another potential drug that targets INAFM1 is the drug basal (24)-azacyclophosphamide (SN-38), which is a topological inhibitor that inhibits the dependence of nucleotide-binding protein (DNA- protein binding protein) activity. INAFM1 is one of the DNA-protein binding proteins. SN-38 can inhibit DNA-protein binding, thereby inhibiting the function of INAFM1.

Biomarker potential

INAFM1 has potential as a biomarker for the diagnosis and prognosis of cancer. The expression of INAFM1 has been shown to be associated with the development and progression of many types of cancer, including breast, ovarian, and colorectal cancers.

In addition, INAFM1 is also closely related to the invasion and metastasis ability of tumor cells. Therefore, by detecting the level of INAFM1 in the blood, the risk of tumor invasion and metastasis can be predicted and help formulate treatment plans.

Conclusion

INAFM1 is a protein that is expressed in various tissues and cells of the human body and plays a key role in the regulation of cell cycle progression and angiogenesis. Because it plays a key role in cell cycle regulation and extracellular matrix production, it has Potential as drug targets and biomarkers. In particular, INAFM1 inhibitors such as sunitinib and SN-38 can inhibit PIKK pathway activity, thereby inhibiting INAFM1 activity. In addition, INAFM1 is also closely related to the invasion and metastasis ability of tumor cells, so by detecting the level of INAFM1 in the blood, the risk of tumor invasion and metastasis can be predicted and help formulate treatment plans.

Protein Name: InaF Motif Containing 1

The "INAFM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INAFM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets